At a glance
ClinicalIndex Comparison RecordN/ACompleted· 131 enrolled
Drug / intervention
Glucerna SRdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4-week, Single-center, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Glucerna SR Using Continuous Glucose Monitoring System(CGMS) in Chinese Drug-naïve Subjects With Type 2 Diabetes
Shanghai Jiao Tong University Affiliated Sixth People's Hospital·interventional·Posted Sep 25, 2014·Updated Jul 1, 2019
In Brief
A clinical study evaluating Glucerna SR for Type 2 Diabetes Mellitus. Completed, enrolled 131 participants across 1 site.
Detailed Summary
The purpose of the study is to evaluate the effect of Glucerna SR treating newly-diagnosed type 2 diabetes patients (NDM) on glycemic stability, with the application of CGMS (continuous glucose monitoring system) and to further realize the safety and effect of Glucerna SR on daily and day-to-day amplitude of blood glucose fluctuation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedSep 2014
Primary CompletionJun 2018
Study CompletionDec 2018
TodayJul 2026
First PostedSep 25, 2014
Enrollment StartMar 1, 2014
Primary CompletionJun 1, 2018
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 11.8 years ago
Interventions
Glucerna SRdietary
Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.